Meriva administration after cryoablation stimulates CD8+ T cells to multiple tumor-associated antigens such as Mage-b and survivin (both expressed in 4T1 tumors), probably through the reduction in IL-6 in the TME. The gene discussed is BIRC5; the disease is neoplasm.